Stockreport

TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE

Trevi Therapeutics, Inc.  (TRVI) 
PDF Enrollment in PRISM Study Progressing - Sample Size Re-estimation Planned for mid-2020 Expect to Report Top-Line Data in both PN and IPF-Cough Trials in Second Half of [Read more]